The future of therapeutic
RNA silencing
1E Therapeutics is a breakthrough drug development company,
creating a novel class of programmable oligonucleotide therapeutics,
designed to treat humanity’s most intractable diseases by autonomously and precisely
silencing disease-causing RNAs in human or pathogen cells
Unique biology.
Differentiated by design.
1E's groundbreaking, patented platform is uniquely able to create safer and more targeted therapies that address chronic and life-threatening indications as well as emerging and evolving pathogens
A single platform addressing a wide array of indications
Genetically driven diseases
Cancer, ALS, Huntington’s
disease, Angelman syndrome
disease, Angelman syndrome
Infectious diseases
Multidrug resistant bacteria
(e.g., MRSA, Pseudomonas,
Klebsiella), RSV
(e.g., MRSA, Pseudomonas,
Klebsiella), RSV
Chronic diseases
CNS disorders, age-related
disorders, metabolic diseases
disorders, metabolic diseases
